| Literature DB >> 31374355 |
Wen-Qiang Cao1, Ying Li2, Ya-Jun Hou3, Mao-Xun Yang4, Xue-Qi Fu5, Bai-Song Zhao4, Han-Ming Jiang6, Xiao-Yan Fu7.
Abstract
Doxorubicin (DOX) as a first-line chemotherapeutic drug has been widely used for therapy of human cancers. However, side effects and chemo-resistance severely blocked its clinic application. Herein, natural borneol (NB) as a novel monoterpenoid chemosensitizer was found to have the potential to increase the blood brain barrier (BBB) permeability and intracellular uptake of DOX in vitro, and synergistically enhanced DOX-induced cytotoxicity in human glioma cells. NB treatment significantly potentiated DOX-induced G2/M cell cycle arrest by triggering reactive oxygen species (ROS)-mediated DNA damage. NB also enhanced DOX-induced dysfunction of MAPKs and PI3 K/AKT pathways. Furthermore, U251 human glioma xenograft growth in vivo was also effectively inhibited by combined treatment of DOX with NB through induction of G2/M-phase arrest and antiangiogenesis. Taken together, our finding validated that NB could act as novel chemosensitizer to enhance DOX-induced anticancer efficacy, and strategy of using NB and DOX could be a high efficient way in therapy of human cancers.Entities:
Keywords: Chemosensitizer; DNA damage; Doxorubicin; Natural borneol; ROS
Year: 2019 PMID: 31374355 DOI: 10.1016/j.biopha.2019.109261
Source DB: PubMed Journal: Biomed Pharmacother ISSN: 0753-3322 Impact factor: 6.529